In CXCR4+ GCB-DLBCL, the frequency of TP53 mutations (which correlated with poor clinical outcomes [41]) was much higher than in CXCR4− GCB-DLBCL (38.3% vs 21.3%, P= .017, Table 2). The gene discussed is CXCR4; the disease is diffuse large B-cell lymphoma.